RAPT Therapeutics, Inc. (RAPT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in RAPT Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

RAPT Therapeutics, Inc. (RAPT) has returned 71.30% so far this year and 494.47% over the past 12 months.

Based on dividend-adjusted daily data since Oct 31, 2019, RAPT's average daily return is +0.26%, while the average monthly return is +3.96%. At this rate, your investment would double in approximately 1.5 years.

Historically, 53% of months were positive and 47% were negative. The best month was Sep 2025 with a return of +126.6%, while the worst month was Feb 2024 at -65.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 3 months.

On a daily basis, RAPT closed higher 49% of trading days. The best single day was Jun 14, 2021 with a return of +115.5%, while the worst single day was Feb 20, 2024 at -73.6%.

RAPT Therapeutics, Inc. has an annualized alpha of 57.85%, beta of 1.28, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 01, 2019.

• This stock participated in 108.43% of S&P 500 Index downside but only 28.72% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RAPT ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for RAPT Therapeutics, Inc. (RAPT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the RAPT Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the RAPT Therapeutics, Inc. was 98.47%, occurring on May 13, 2025. The portfolio has not yet recovered.

The current RAPT Therapeutics, Inc. drawdown is 85.16%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of RAPT Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how RAPT Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.